About the Study

Solid Tumors: A study of Silmitasertib (CX-4945) for relapsed or refractory solid tumors

This study is for: • Patients less than 30 years old at initial diagnosis • Who have been diagnosed with refractory (has not responded to earlier treatment) or relapsed (has come back) solid tumor - Phase I of the study includes Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, and Liposarcoma - Phase II of the study includes Neuroblastoma and Ewing Sarcoma The goal of this study for Phase I is to find the recommended dose for Phase II. The goal of this study for both Phases I & II is to find what effects, good and/or bad, the drug silmitasertib has on children and young adults with relapsed or refractory solid tumors.

This study does not take place at Children’s Mercy.

Interested in learning more?

Full Study Name: BCC021